Svetlana Lucas
Svetlana Lucas's purchase track record
Svetlana Lucas has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/23/2026 | SCTX | $45K | pending | pending | — |
| 9/22/2025 | JSPR | $49K | -24.8% | -53.1% | -1.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Jasper Therapeutics Names Interim CFO. Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
aTyr Pharma Aligns With FDA On Phase 3 Efzofitimod Plan. aTyr Pharma announced it has reached alignment with the FDA on the protocol for a Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. The company expects to begin study-related activities in the fourth quarter of 2026. This regulatory progress follows a period where the stock traded near its 52-week low, indicating a significant step in the drug's development timeline.
Transaction History
| SCTX | ▲ Buy | Open Market | 3,000 | $45K | 7/23/2026 | View on chart |
| JSPR | ▲ Buy | Open Market | 20,000 | $49K | 9/22/2025 | View on chart |
| ATYR | ▲ Buy | Option Exercise | 6,000 | — | 4/26/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Cathie Wood's ARKG adds Scribe Therapeutics to its biotech holdings
ARK Genomic Revolution ETF (ARKG) increased its position in Scribe Therapeutics, as reported by Yahoo and Benzinga. The addition places Scribe among four biotech names that the fund has recently loaded up on. The stock also appeared in a list of health‑care shares moving in the pre‑market session. This news brings additional attention to the company while the stock shows modest momentum on the chart.
Cathie Wood's ARKG adds Scribe Therapeutics to its biotech holdings. ARK Genomic Revolution ETF (ARKG) increased its position in Scribe Therapeutics, as reported by Yahoo and Benzinga. The addition places Scribe among four biotech names that the fund has recently loaded up on. The stock also appeared in a list of health‑care shares moving in the pre‑market session. This news brings additional attention to the company while the stock shows modest momentum on the chart.